Neovasc to Participate in H.C. Wainwright Global Investment Conference
May 23 2022 - 4:05PM
via NewMediaWire -- Neovasc, Inc. (Neovasc or the
Company) (NASDAQ , TSX : NVCN) today announced that
its management team will be participating in the H.C. Wainwright
Global Investment Conference to be held May 23-26, 2022. Fred
Colen, Neovasc’s President and Chief Executive Officer, will be
presenting at 11:00 am ET on Wednesday, May 25.
A live webcast of Mr. Colen’s presentation can be
accessed using the link available in the Investors section of the
Neovasc website here. Additionally, a recording of the
presentation will be available via the same link, and will be
archived for 90 days.
About Neovasc Inc.Neovasc is a specialty
medical device company that develops, manufactures, and markets
products for the rapidly growing cardiovascular marketplace. Its
products include Reducer, for the treatment of refractory angina,
which is under clinical investigation in the United States and has
been commercially available in Europe since 2015, and Tiara™ for
the transcatheter treatment of mitral valve disease, which is
currently under clinical investigation in the United States,
Canada, Israel and Europe. For more information,
visit: www.neovasc.com.
Forward-Looking Statement DisclaimerCertain
statements in this news release contain forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and applicable Canadian securities laws that may not be
based on historical fact. When used herein, the words expect,
anticipate, estimate, may, will, should, intend, believe, and
similar expressions, are intended to identify forward-looking
statements. Forward-looking statements may involve, but are not
limited to, the growing cardiovascular marketplace. Forward-looking
statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical
trends, current conditions and expected future developments, as
well as other factors that the Company believes are appropriate in
the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the Risk Factors section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the year ended December 31, 2021
(copies of which may be obtained
at www.sedar.com or www.sec.gov). These factors
should be considered carefully, and readers should not place undue
reliance on the Company’s forward-looking statements. The Company
has no intention and undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
ContactsInvestorsMike
CavanaughWestwicke/ICRPhone:
+1.617.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICRPhone:
+1.646.866.4012Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024